- Home
- TEAF vs NKTR Comparison
TEAF vs NKTR Comparison
Compare TEAF & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- NKTR
- Stock Information
- Founded
- TEAF 2017
- NKTR 1990
- Country
- TEAF United States
- NKTR United States
- Employees
- TEAF N/A
- NKTR N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- TEAF Finance
- NKTR Health Care
- Exchange
- TEAF Nasdaq
- NKTR Nasdaq
- Market Cap
- TEAF 174.8M
- NKTR 160.4M
- IPO Year
- TEAF N/A
- NKTR 1994
- Fundamental
- Price
- TEAF $11.11
- NKTR $0.64
- Analyst Decision
- TEAF
- NKTR Strong Buy
- Analyst Count
- TEAF 0
- NKTR 6
- Target Price
- TEAF N/A
- NKTR $4.92
- AVG Volume (30 Days)
- TEAF 56.1K
- NKTR 2.8M
- Earning Date
- TEAF 01-01-0001
- NKTR 05-08-2025
- Dividend Yield
- TEAF 9.20%
- NKTR N/A
- EPS Growth
- TEAF N/A
- NKTR N/A
- EPS
- TEAF N/A
- NKTR N/A
- Revenue
- TEAF N/A
- NKTR $98,427,000.00
- Revenue This Year
- TEAF N/A
- NKTR N/A
- Revenue Next Year
- TEAF N/A
- NKTR N/A
- P/E Ratio
- TEAF N/A
- NKTR N/A
- Revenue Growth
- TEAF N/A
- NKTR 9.21
- 52 Week Low
- TEAF $11.11
- NKTR $0.43
- 52 Week High
- TEAF $13.30
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- TEAF 47.96
- NKTR 45.85
- Support Level
- TEAF $10.09
- NKTR $0.43
- Resistance Level
- TEAF $11.58
- NKTR $0.68
- Average True Range (ATR)
- TEAF 0.25
- NKTR 0.08
- MACD
- TEAF 0.04
- NKTR 0.01
- Stochastic Oscillator
- TEAF 68.46
- NKTR 72.41
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.